Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Divests Select China Prevenar 13 Rights, Staff As Domestic Firms Gain Traction

Competitive Presence Needed

Executive Summary

Following in the steps of Merck & Co. and GSK, Pfizer is turning to a Chinese partner to more broadly market one of its top vaccines in the country - but the US firm is going one step further.

You may also be interested in...



Asia Deal Watch: Dr Reddy’s Licenses Coya’s ALS Combo Drug

Plus deals involving Abbisko/Merck & Co., Astellas/Phenomic AI, PRISM Biolab/Lilly and WuXi Biologics/Myricx.

Chinese Language Podcast: Biokin/BMS Deal, Developments At Pfizer, BlissBio, WuXi Biologics

Chengdu-based Biokin has just signed a $8.4bn licensing deal with BMS for an ADC asset, while Pfizer is turning to a Chinese partner to more broadly market one of its top vaccines in China. Meanwhile, BlissBio has released new clinical data for its HER2-targeting ADC and shares in WuXi Biologics have plummeted following its latest business updates.

China Respiratory Disease Surge Prompts WHO Info Request

Since October, reported cases of infectious respiratory diseases have been rising in China, prompting an information request from the WHO. However, no new types of pathogen or unusual clinical symptoms have been detected so far.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel